Across TCGA pan-cancer cohorts, CDRT15L2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CDRT15L2 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher CDRT15L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDRT15L2 expression acts as an unfavorable survival marker.

SARC are the cancer types where CDRT15L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.201	0.766	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: CDRT15L2 tumor-vs-normal RNA expression · all CDRT15L2 data types